Treatment Action Group (TAG) released an overview of TB research data reported at CROI 2026. Highlights include results from several studies that answered questions on how to give 3HP and 1HP with the HIV medicine dolutegravir (including data for children and pregnant persons); insights into a targeted linezolid dosing strategy; and preclinical data on long-acting pretomanid and TBAJ-876 (sorfequiline). A plenary session on the last day of the conference focused on the major progress made in closing TB treatment and diagnostic evidence gaps for children and the importance of including children and mothers early in clinical research.
A summary of major findings and TAG’s analysis are available here.
Source : Treatment Action Group
Related HIV and Co-Infections News
-
[CROI 2026] HIV i-Base: GLP-1 weight loss drugs include potential immune benefits in gut tissue
-
University of Cape Town: New modelling study shows impact of late stage TB vaccines depends on their ability to prevent infectious, asymptomatic TB
-
Health Policy Watch: Global Fund faces $5bn shortfall as France slashes support, EU delays pledge
Get involved
Are you living with HIV/AIDS? Are you part of a community affected by HIV/AIDS and co-infections? Do you work or volunteer in the field? Are you motivated by our cause and interested to support our work?
Subscribe
Stay in the loop and get all the important EATG updates in your inbox with the EATG newsletter. The HIV & co-infections bulletin is your source of handpicked news from the field arriving regularly to your inbox.